Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
7635 | 1345 | 33.4 | 58% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
11 | 4 | NEUROSCIENCES//CLINICAL NEUROLOGY//NEUROL | 1112395 |
209 | 3 | GHRELIN//ADRENOMEDULLIN//NEUROPEPTIDE Y | 51926 |
1319 | 2 | ADRENOMEDULLIN//AMYLIN//ISLET AMYLOID POLYPEPTIDE | 8452 |
7635 | 1 | CALCITONIN//SALMON CALCITONIN//CALCITONIN RECEPTOR | 1345 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | CALCITONIN | authKW | 1032998 | 19% | 18% | 249 |
2 | SALMON CALCITONIN | authKW | 580800 | 6% | 35% | 74 |
3 | CALCITONIN RECEPTOR | authKW | 374201 | 3% | 39% | 42 |
4 | HUMAN CALCITONIN | authKW | 111738 | 1% | 31% | 16 |
5 | CALCITONIN RECEPTOR STIMULATING PEPTIDE | authKW | 102152 | 0% | 75% | 6 |
6 | NASAL SALMON CALCITONIN | authKW | 94587 | 0% | 83% | 5 |
7 | SALMON CALCITONIN NASAL SPRAY | authKW | 90805 | 0% | 100% | 4 |
8 | ELCATONIN | authKW | 88334 | 1% | 32% | 12 |
9 | 5 CNAC | authKW | 68104 | 0% | 100% | 3 |
10 | INTERATENEO FIS | address | 68104 | 0% | 100% | 3 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Endocrinology & Metabolism | 10855 | 35% | 0% | 469 |
2 | Pharmacology & Pharmacy | 1579 | 22% | 0% | 293 |
3 | Rheumatology | 458 | 4% | 0% | 49 |
4 | Medicine, Research & Experimental | 291 | 7% | 0% | 89 |
5 | Biochemistry & Molecular Biology | 140 | 13% | 0% | 176 |
6 | Medicine, General & Internal | 116 | 6% | 0% | 81 |
7 | Orthopedics | 94 | 3% | 0% | 39 |
8 | Neurosciences | 89 | 7% | 0% | 100 |
9 | Biophysics | 72 | 4% | 0% | 51 |
10 | Geriatrics & Gerontology | 39 | 1% | 0% | 16 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | INTERATENEO FIS | 68104 | 0% | 100% | 3 |
2 | MED 1 MED PATHOL CLIN METHODOL | 30267 | 0% | 67% | 2 |
3 | INTERNAL MED RHEUMATOL OSTEOL 2 | 25535 | 0% | 38% | 3 |
4 | ABORAT PUBL HLTH ASPECTS OSTEOARTICULAR D | 22701 | 0% | 100% | 1 |
5 | AMER NUTR | 22701 | 0% | 100% | 1 |
6 | ANS UYGULAMA ARASTRIRMA HASTANESI FIZ TEDAVI KLIN | 22701 | 0% | 100% | 1 |
7 | BIOL CELULAR NEUROCIENCIAS PROF E DEROBERT | 22701 | 0% | 100% | 1 |
8 | BONE METAB UNIT INVEST CLIN HJ TAGNON | 22701 | 0% | 100% | 1 |
9 | CALCITONIN BIOL SAFETY | 22701 | 0% | 100% | 1 |
10 | CALCITONIN BIOL SAFETY UNIT | 22701 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | CALCIFIED TISSUE INTERNATIONAL | 25028 | 5% | 2% | 73 |
2 | BONE AND MINERAL | 7247 | 1% | 2% | 15 |
3 | ENDOCRINOLOGY | 4669 | 5% | 0% | 72 |
4 | CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 3943 | 2% | 1% | 29 |
5 | BONE | 3238 | 2% | 0% | 31 |
6 | ITALIAN JOURNAL OF MINERAL & ELECTROLYTE METABOLISM | 3235 | 0% | 4% | 4 |
7 | ACTA ENDOCRINOLOGICA | 2775 | 2% | 1% | 22 |
8 | HORMONE AND METABOLIC RESEARCH | 2578 | 2% | 0% | 27 |
9 | JOURNAL OF BONE AND MINERAL RESEARCH | 1618 | 2% | 0% | 22 |
10 | JAPANESE JOURNAL OF PHARMACOLOGY | 1300 | 1% | 0% | 16 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CALCITONIN | 1032998 | 19% | 18% | 249 | Search CALCITONIN | Search CALCITONIN |
2 | SALMON CALCITONIN | 580800 | 6% | 35% | 74 | Search SALMON+CALCITONIN | Search SALMON+CALCITONIN |
3 | CALCITONIN RECEPTOR | 374201 | 3% | 39% | 42 | Search CALCITONIN+RECEPTOR | Search CALCITONIN+RECEPTOR |
4 | HUMAN CALCITONIN | 111738 | 1% | 31% | 16 | Search HUMAN+CALCITONIN | Search HUMAN+CALCITONIN |
5 | CALCITONIN RECEPTOR STIMULATING PEPTIDE | 102152 | 0% | 75% | 6 | Search CALCITONIN+RECEPTOR+STIMULATING+PEPTIDE | Search CALCITONIN+RECEPTOR+STIMULATING+PEPTIDE |
6 | NASAL SALMON CALCITONIN | 94587 | 0% | 83% | 5 | Search NASAL+SALMON+CALCITONIN | Search NASAL+SALMON+CALCITONIN |
7 | SALMON CALCITONIN NASAL SPRAY | 90805 | 0% | 100% | 4 | Search SALMON+CALCITONIN+NASAL+SPRAY | Search SALMON+CALCITONIN+NASAL+SPRAY |
8 | ELCATONIN | 88334 | 1% | 32% | 12 | Search ELCATONIN | Search ELCATONIN |
9 | 5 CNAC | 68104 | 0% | 100% | 3 | Search 5+CNAC | Search 5+CNAC |
10 | HYPOCALCEMIC ACTIVITY | 63054 | 0% | 56% | 5 | Search HYPOCALCEMIC+ACTIVITY | Search HYPOCALCEMIC+ACTIVITY |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | SEXTON, PM , FINDLAY, DM , MARTIN, TJ , (1999) CALCITONIN.CURRENT MEDICINAL CHEMISTRY. VOL. 6. ISSUE 11. P. 1067 -1093 | 156 | 56% | 115 |
2 | CRANNEY, A , TUGWELL, P , ZYTARUK, N , ROBINSON, V , WEAVER, B , SHEA, B , WELLS, G , ADACHI, J , WALDEGGER, L , GUYATT, G , (2002) META-ANALYSIS OF CALCITONIN FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS.ENDOCRINE REVIEWS. VOL. 23. ISSUE 4. P. 540 -551 | 48 | 86% | 76 |
3 | PURDUE, BW , TILAKARATNE, N , SEXTON, PM , (2002) MOLECULAR PHARMACOLOGY OF THE CALCITONIN RECEPTOR.RECEPTORS & CHANNELS. VOL. 8. ISSUE 3-4. P. 243-255 | 65 | 61% | 61 |
4 | PLOSKER, GL , MCTAVISH, D , (1996) INTRANASAL SALCATONIN (SALMON CALCITONIN) - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND ROLE IN THE MANAGEMENT OF POSTMENOPAUSAL OSTEOPOROSIS.DRUGS & AGING. VOL. 8. ISSUE 5. P. 378-400 | 68 | 71% | 40 |
5 | CHESNUT, CH , AZRIA, M , SILVERMAN, S , ENGELHARDT, M , OLSON, M , MINDEHOLM, L , (2008) SALMON CALCITONIN: A REVIEW OF CURRENT AND FUTURE THERAPEUTIC INDICATIONS.OSTEOPOROSIS INTERNATIONAL. VOL. 19. ISSUE 4. P. 479-491 | 49 | 58% | 68 |
6 | BEVIS, PJR , HUANG, CLH , ZAIDI, M , INZERILLO, AM , MOONGA, BS , (2002) FORTY YEARS OF CALCITONIN - WHERE ARE WE NOW? A TRIBUTE TO THE WORK OF IAIN MACINTYRE, FRS.BONE. VOL. 30. ISSUE 5. P. 655 -663 | 68 | 47% | 82 |
7 | BODY, JJ , (2002) CALCITONIN FOR THE LONG-TERM PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS.BONE. VOL. 30. ISSUE 5. P. 75S-79S | 36 | 88% | 42 |
8 | BRAGA, PC , (1994) CALCITONIN AND ITS ANTINOCICEPTIVE ACTIVITY - ANIMAL AND HUMAN INVESTIGATIONS 1975-1992.AGENTS AND ACTIONS. VOL. 41. ISSUE 3-4. P. 121-131 | 50 | 82% | 37 |
9 | KAPURNIOTU, A , (2004) CONTRIBUTION OF CONFORMATIONALLY CONSTRAINED CALCITONIN (CT) ANALOGS TO THE UNDERSTANDING OF THE STRUCTURAL AND CONFORMATIONAL REQUIREMENTS OF CALCITONIN BIOACTIVITY AND TO THE DESIGN OF POTENT AGONISTS.CURRENT MEDICINAL CHEMISTRY. VOL. 11. ISSUE 21. P. 2845-2865 | 55 | 55% | 3 |
10 | HUANG, CLH , SUN, L , MOONGA, BS , ZAIDI, M , (2006) MOLECULAR PHYSIOLOGY AND PHARMACOLOGY OF CALCITONIN.CELLULAR AND MOLECULAR BIOLOGY. VOL. 52. ISSUE 3. P. 33-43 | 58 | 48% | 16 |
Classes with closest relation at Level 1 |